Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-CLS-628 in adults with autosomal dominant polycystic kidney disease
NL-OMON59984Phase 2Active, not recruiting
- Sponsor
- Calico Life Sciences
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of ABBV-CLS-628 in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Calico Life Sciences. Primary endpoint: Cumulative rate of change from baseline in total kidney volume by MRI at Week 96. Started Aug 2025; status: active, not recruiting.
02
Drugs
ABBV-CLS-628
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON59984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59984.